Renovis Cuts Workforce By 40 Percent To Focus On Preclinical Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
Eliminations follow Phase III failure of an acute ischemic stroke candidate that had been in development with AstraZeneca.